Goldline Pharmaceutical Limite
BSE: GLPL · Pharmaceuticals · sector
₹31.99BSE close 2026-10-26
Key numbers
Market cap₹22 cr
Price₹31.99
52w high / low₹60 / ₹28
P/E5.4xSector median 27.9x
P/B4.0xSector median 2.9x
Book value₹8.0
Dividend yield0.98%Sector median 0.48%
ROE74.3%Sector median 11.7%
ROCE120.9%Sector median 12.3%
OPM22.2%Sector median 14.0%
Debt / equity–Sector median 0.16x
EV/EBITDA3.1xSector median 18.6x
Interest cover5.1x
Current ratio2.15x
Sales growth 3y–Sector median +9.6%
Profit growth 3y–Sector median +13.3%
PEG–
Last 12 months to Mar 2026, Standalone. "Sector median" = middle value of 185 companies in Pharmaceuticals (P/E median leaves out loss-making companies). Tap ? for what a number means.
Things to know
- Operating profit covered interest 5.1x in the last 12 months.
- Other income was 0% of net profit in the last 12 months.
- No dividend in the last 1 financial years.
- Price ₹31.99 on 2026-10-26: -46.7% from the 52-week high, +13.7% from the 52-week low.
Plain facts from the filings, built by the same fixed rules for every company. A line appears only when the data for it is available. Not a view on the stock.
Charts
Weekly close · high ₹46.57 · low ₹30.97
RevenueNet profit
RevenueNet profit
Quarterly results
| ₹ cr | Mar 2026 |
|---|---|
| Revenue | 17 |
| EBITDA | 4 |
| OPM % | 24.8% |
| Other income | 0 |
| Net profit | 3 |
| EPS (₹) | 3.43 |
Standalone figures where filed. Latest quarter Mar 2026.
Profit & loss (yearly)
| ₹ cr | FY26 | TTM |
|---|---|---|
| Revenue | 31 | 31 |
| EBITDA | 7 | 7 |
| Net profit | 4 | 4 |
| EPS (₹) | 5.97 | 5.97 |
| Dividend / share (₹) | – |
| Compounded growth | 3 years | 5 years | Last 12 months |
|---|---|---|---|
| Sales | – | – | – |
| Net profit | – | – | – |
| EPS | – | – | – |
| Share price | – | – (2y) | – |
Balance sheet
| ₹ cr | FY26 |
|---|---|
| Shareholders' equity | 6 |
| Cash & equivalents | 1 |
| Total assets | 29 |
| Fixed assets | 3 |
| Investments | 0 |
| Inventory | 6 |
Year-end figures from the March annual filing.
Cash flow
| ₹ cr | FY26 |
|---|---|
| Cash from operations | 3 |
| Cash from investing | -0 |
| Cash from financing | -3 |
| Capex | 0 |
| Free cash flow | 3 |
Free cash flow = cash from operations − capex.
Ratios by year
| ₹ cr | FY26 |
|---|---|
| ROE % | 74.3% |
| ROCE % | 120.9% |
| Inventory days | 203 |
| Working capital days | 163 |
Peers in Pharmaceuticals
| Company | Market cap | P/E | P/B | ROE | ROCE | OPM | Sales 3y | Div yield |
|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹4,17,478 cr | 34.5x | 5.0x | 15.5% | 18.7% | 28.6% | +10.0% | 0.94% |
| DIVISLAB | ₹2,39,825 cr | 82.1x | 14.3x | 18.4% | 23.0% | 34.7% | +10.8% | 0.34% |
| TORNTPHARM | ₹1,53,999 cr | 72.7x | 18.4x | 27.3% | 15.1% | 32.3% | +13.3% | 0.84% |
| ZYDUSLIFE | ₹1,15,808 cr | 25.9x | 4.3x | 17.7% | 16.8% | 27.2% | +16.4% | 0.95% |
| LAURUSLABS | ₹1,11,232 cr | 101.6x | 21.0x | 22.4% | 20.8% | 28.0% | +4.1% | 0.08% |
| CIPLA | ₹1,09,464 cr | 32.5x | 3.2x | 10.3% | 13.2% | 17.7% | +7.4% | 1.18% |
| DRREDDY | ₹1,09,460 cr | 33.9x | 2.9x | 9.0% | 10.1% | 15.5% | +11.0% | 0.61% |
| MANKIND | ₹95,486 cr | 46.7x | 5.9x | 13.4% | 13.8% | 25.1% | +17.7% | 0.04% |
| AUROPHARMA | ₹91,489 cr | 24.9x | 2.4x | 10.5% | 12.8% | 20.0% | +10.6% | 0.26% |
| GLPL | ₹22 cr | 5.4x | 4.0x | 74.3% | 120.9% | 22.2% | – | 0.98% |
Documents
Links go to the original files on the exchange website.
About the company
| Sector | Healthcare |
| Industry | Pharmaceuticals |
| Sub-industry | Pharmaceuticals |
| Symbol | GLPL |
| BSE code | 544759 |
| ISIN | INE1CLW01015 |
| Face value | ₹10.0 |
| Incorporated | – |
| Website | – |
| Plants (India / abroad) | – |
Data built 2026-10-23 from BSE company filings (inline XBRL: Integrated Filing - Finance) + BSE results summary for earlier years; price = BSE close 2026-10-26.